Status: Recruiting
Study of APR-1051 in Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Aprea TherapeuticsUpdated: Aug 17, 2026Locations: 5
Eligibility criteria
Age ≥ 18 years [+6]
Patient has had prior systemic anti-cancer therapy (cytotoxic chemotherapy, immu... [+5]